BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6376721)

  • 21. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model.
    Romaguera JE; McLaughlin P; North L; Dixon D; Silvermintz KB; Garnsey LA; Velasquez WS; Hagemeister FB; Cabanillas F
    J Clin Oncol; 1991 May; 9(5):762-9. PubMed ID: 1707956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
    Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
    Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
    Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
    J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy.
    Shipp MA; Klatt MM; Yeap B; Jochelson MS; Mauch PM; Rosenthal DS; Skarin AT; Canellos GP
    J Clin Oncol; 1989 May; 7(5):613-8. PubMed ID: 2468746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
    Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
    J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.
    Decaudin D; Lepage E; Brousse N; Brice P; Harousseau JL; Belhadj K; Tilly H; Michaux L; Chèze S; Coiffier B; Solal-Céligny P
    J Clin Oncol; 1999 Aug; 17(8):2499-505. PubMed ID: 10561315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan.
    Katsumata N; Matsuno Y; Nakayama H; Takenaka T; Kobayashi Y; Takeyama K; Narabayashi M; Fukushima T; Yokozawa T; Nakata M; Tajima K; Ikeda H; Tobinai K
    Jpn J Clin Oncol; 1996 Dec; 26(6):445-54. PubMed ID: 9001350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment strategies in limited stage follicular NHL.
    Hoppe RT
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):179-86. PubMed ID: 21658617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognostic factors of follicular lymphoma treated with combination chemotherapy].
    Niitsu N; Umeda M
    Rinsho Ketsueki; 1997 Jun; 38(6):496-504. PubMed ID: 9248325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
    Link BK; Martin P; Kaminski MS; Goldsmith SJ; Coleman M; Leonard JP
    J Clin Oncol; 2010 Jun; 28(18):3035-41. PubMed ID: 20458031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.
    Solal-Céligny P; Lepage E; Brousse N; Tendler CL; Brice P; Haïoun C; Gabarre J; Pignon B; Tertian G; Bouabdallah R; Rossi JF; Doyen C; Coiffier B
    J Clin Oncol; 1998 Jul; 16(7):2332-8. PubMed ID: 9667247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
    Coiffier B; Gisselbrecht C; Vose JM; Tilly H; Herbrecht R; Bosly A; Armitage JO
    J Clin Oncol; 1991 Feb; 9(2):211-9. PubMed ID: 1703226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of radiotherapy and combined modality treatment in early stage high grade non-Hodgkin's lymphoma.
    Frank C; Flentje M; Goldschmidt H; Hunstein W; Wannenmacher M
    Strahlenther Onkol; 1994 Jul; 170(7):383-90. PubMed ID: 8052937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage chemotherapy with IAPVP-16 for advanced refractory or relapsed follicular lymphomas.
    López R; Martino R; Brunet S; Sureda A; Domingo-Albós A; Sierra J
    Haematologica; 1999 Oct; 84(10):911-6. PubMed ID: 10509039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.
    Brice P; Bastion Y; Divine M; Nedellec G; Ferrant A; Gabarre J; Reman O; Lepage E; Fermé C
    Cancer; 1996 Sep; 78(6):1293-9. PubMed ID: 8826953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Follicular lymphoma in Japan: retrospective study on natural history and therapeutic results in 50 cases collected from 4 institutions].
    Takagi T; Sampi K; Sawada U; Kuraishi Y; Takagi K; Mikata A
    Rinsho Ketsueki; 1989 Dec; 30(12):2123-8. PubMed ID: 2695661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment outcome and prognostic factors for primary nasal lymphoma.
    Liang R; Todd D; Chan TK; Chiu E; Lie A; Kwong YL; Choy D; Ho FC
    J Clin Oncol; 1995 Mar; 13(3):666-70. PubMed ID: 7884427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.